Looking for Ozempic? Doctors are prescribing these diabetic alternatives for now – Connecticut Public

Currently, 186 drugs are in the FDA’s shortages list. Among them – the antibiotic amoxicillin, the ADHD drug Adderall and now Ozempic.
Pharma company Novo Nordisk – maker of the weekly injectable drug Ozempic (semaglutide) for type 2 diabetes, touts its weight loss benefit in its advertising. Adults, the company claims, lost up to 12 pounds. But that’s not why the drug was first approved by the Food and Drug Administration (FDA) in 2017.
Novo Nordisk’s data shows patients with type 2 diabetes are seeing their hemoglobin A1C levels drop to under 7. According to the American Diabetes Association, an A1C level of 6.5 and above indicates diabetes.
Normally, obesity physicians prescribe Wegovy for weight loss. But, about two months ago, supplies of Wegovy dwindled because of surging demand, driven, in part, by social media promotion. And so obesity physicians, including Dr. Devika Umashankar of Hartford HealthCare, began prescribing Ozempic for weight loss because both Wegovy and Ozempic contain the same medication – semaglutide – but are dosed differently for weight loss and type 2 diabetes.
“And what we have seen is, with this approach, it has now caused Ozempic to become a shortage,” Umashankar says. “I can tell you, it’s become more prominent in our clinical population, in the last one to two months, where patients are unable to find the medication within their local city or town.”
It is common for physicians to prescribe drugs for off-label use. For example, the heart failure drug Ivabradine is frequently prescribed to manage symptoms among patients with postural orthostatic tachycardia syndrome (POTS). Gabapentin, approved for seizures, is prescribed off-label for hot flashes.
Novo Nordisk told Connecticut Public Radio that its global manufacturing facilities are now operating 24/7, seven days a week, to help ease supply constraints. The supply is expected to be back up by March of 2023. In the meantime, doctors are prescribing alternatives. The weekly injectable Trulicy from Eli Lilly is a close substitute.
But, Umashankar said there “appears to be a little bit of a shortage as well” for Trulity. “Not that it’s been formally announced, but it’s been backordered.”
So she and her colleagues are switching patients to a daily injectable also from Novo Nordisk.
“We are switching patients to other GLP-1 medications,” she said. “For example, if Trulicity is not available, then Victoza beta glutide, 1.8 milligrams.”
Umashankar says patients must call their doctors for an alternate diabetic drug. Another adverse impact of this shortage she said is patients have lower compliance levels with a daily, compared to a weekly, injectable.
This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.
We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.
Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

source